Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Theratechnologies Inc.
  6. News
  7. Summary
    TH   CA88338H1001

THERATECHNOLOGIES INC.

(TH)
  Report
Delayed Toronto Stock Exchange  -  03:59:59 2023-01-27 pm EST
1.240 CAD   -0.80%
01/05Theratechnologies Inc. - Open Letter to Shareholders from CEO Paul Levesque
AQ
01/05World Orphan Drug Alliance Announces Long-Term, Multi-Territorial Distribution Agreement with Theratechnologies Inc. for Distribution of EGRIFTA SV
CI
01/04National Bank on Theratechnologies
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Theratechnologies Inc Announces Update from Ongoing TH1902 Study

12/01/2022 | 06:30pm EST

Theratechnologies Inc. announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company's lead investigational peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration (FDA) for approval. Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators.

Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity. The current intent for the protocol amendment is to modify the dosage regimen to optimize the delivery of TH1902, with lower doses at more frequent intervals.

The Company continues to investigate the results obtained thus far in the Phase 1 clinical trial.


© S&P Capital IQ 2022
All news about THERATECHNOLOGIES INC.
01/05Theratechnologies Inc. - Open Letter to Shareholders from CEO Paul Levesque
AQ
01/05World Orphan Drug Alliance Announces Long-Term, Multi-Territorial Distribution Agreemen..
CI
01/04National Bank on Theratechnologies
MT
01/04Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan's Key Objectiv..
MT
01/04Theratechnologies Brief: Announcing Fiscal Year 2023 Guidance an..
MT
01/04Open Letter to Shareholders from CEO Paul Levesque
GL
01/04Open Letter to Shareholders from CEO Paul Levesque
GL
01/04Theratechnologies Inc. Provides Revenue Guidance for the Fiscal Year 2022 and Earnings ..
CI
2022Sector Update: Health Care Stocks Rise Friday
MT
2022Sector Update: Healthcare
MT
More news
Analyst Recommendations on THERATECHNOLOGIES INC.
More recommendations
Financials
Sales 2022 109 M 81,9 M 81,9 M
Net income 2022 -63,8 M -47,9 M -47,9 M
Net Debt 2022 - - -
P/E ratio 2022 -1,93x
Yield 2022 -
Capitalization 118 M 88,6 M 88,6 M
Capi. / Sales 2022 1,08x
Capi. / Sales 2023 0,93x
Nbr of Employees 87
Free-Float 98,8%
Chart THERATECHNOLOGIES INC.
Duration : Period :
Theratechnologies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERATECHNOLOGIES INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,24 CAD
Average target price 3,50 CAD
Spread / Average Target 182%
EPS Revisions
Managers and Directors
Paul Lévesque President, Chief Executive Officer & Director
Philippe Dubuc Chief Financial Officer & Senior Vice President
Dawn A. Svoronos Chairman
Christian Marsolais Chief Medical Officer & Senior Vice President
Gérald A. Lacoste Independent Director
Sector and Competitors